In this perspective, we argue that pubertal suppression with gonadotropin-releasing hormone analogues is a safe reversible intervention that should be made available to transgender and gender-diverse youth starting at early puberty. Recent data suggest puberty suppression is generally initiated among individuals once puberty has significantly progressed, thus reducing the effectiveness of the intervention. Delays and barriers to such care may systematically introduce permanent avoidable disadvantages for this vulnerable and marginalized group.
Get full access to this article
View all access options for this article.
References
1.
Rafferty J; Committee on Psychosocial Aspects of Child and Family Health; Committee onAdolescence, et al.Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics. 2018; 142:e20182162.
2.
GrantJM, MottetLA, TanisJ, et al. Injustice at every turn: a report of the National Transgender Discrimination Survey. Available at: https://www.thetaskforce.org/injustice-every-turn-report-national-transgender-discrimination-survey. Accessed November29, 2020.
3.
van der MiesenAIR, SteensmaTD, de VriesALC, et al.Psychological functioning in transgender adolescents before and after gender-affirmative care compared with cisgender general population peers. J Adolesc Health. 2020; 66:699–704.
4.
ArnoldussenM, SteensmaTD, PopmaA, et al.Re-evaluation of the Dutch approach: are recently referred transgender youth different compared to earlier referrals?. Eur Child Adolesc Psychiatry. 2020; 29:803–811.
5.
Cohen-KettenisPT, van GoozenSH. Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. Eur Child Adolesc Psychiatry. 1998; 7:246–248.
6.
ChewD, AndersonJ, WilliamsK, et al.Hormonal treatment in young people with gender dysphoria: a systematic review. Pediatrics. 2018; 141:e20173742.
7.
HembreeWC, Cohen-KettenisP, Delemarre-van de WaalHA, et al.Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94:3132–3154.
8.
HembreeWC, Cohen-KettenisPT, GoorenL, et al.Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017; 102:3869–3903.
9.
ColemanE, BocktingW, BotzerM, et al.Standards of care for the health of transsexual, transgender, and gender-nonconforming people, version 7. Int J Transgend. 2012; 13:165–232.
10.
DeutschMB. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. 2nd ed. June 17, 2016. Available at: https://transcare.ucsf.edu/guidelines. Accessed November29, 2020.
11.
TurbanJL, KingD, CarswellJM, KeuroghlianAS. Pubertal suppression for transgender youth and risk of suicidal ideation. Pediatrics. 2020; 145:e20191725.
12.
KleinDA, EmerickJE, SylvesterJE, VogtKS. Disorders of puberty: an approach to diagnosis and management. Am Fam Physician. 2017; 96:590–599.
13.
GülgözS, GlazierJJ, EnrightEA, et al.Similarity in transgender and cisgender children's gender development. Proc Natl Acad Sci U S A. 2019; 116:24480–24485.
14.
LaiTC, McDougallR, FeldmanD, et al.Fertility counseling for transgender adolescents: a review. J Adolesc Health. 2020; 66:658–665.
15.
ChenD, StrangJF, KolbuckVD, et al.Consensus parameter: research methodologies to evaluate neurodevelopmental effects of pubertal suppression in transgender youth. Transgend Health. 2020; 5:246–257.
16.
U.S. Department of Health and Human Services. Rule on Section 1557. 2020. Available at: https://www.hhs.gov/about/news/2020/06/12/hhs-finalizes-rule-section-1557-protecting-civil-rights-healthcare.html. Accessed August31, 2020.
17.
LauJS, Kline-SimonA, SterlingS, et al. Screening for gender identity in adolescent well visits: is it feasible and acceptable? J Adolesc Health. 2020 [Epub ahead of print]; DOI: 10.1016/j.jadohealth.2020.07.031.
18.
PangKC, NotiniL, McDougallR, et al.Long-term puberty suppression for a nonbinary teenager. Pediatrics. 2020; 145:e20191606.
19.
SorbaraJC, ChiniaraLN, ThompsonS, PalmertMR. Mental health and timing of gender-affirming care. Pediatrics. 2020; 146:e20193600.
20.
de VriesALC. Challenges in timing puberty suppression for gender-nonconforming adolescents. Pediatrics. 2020; 146:e2020010611.
21.
BrikT, VrouenraetsLJJJ, de VriesMC, HannemaSE. Trajectories of adolescents treated with gonadotropin-releasing hormone analogues for gender dysphoria. Arch Sex Behav. 2020; 49:2611–2618.
22.
KuperLE, StewartS, PrestonS, et al.Body dissatisfaction and mental health outcomes of youth on gender-affirming hormone therapy. Pediatrics. 2020; 145:e20193006.
